Telix partners with Subtle Medical on PSMA-PET software

Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio.

SubtlePET is a U.S. Food and Drug Administration (FDA) cleared deep-learning algorithm designed to enhance the efficiency and effectiveness of imaging procedures, Telix said. The algorithm allows for faster PET scanning, up to 75% faster without compromising image quality, according to the company.

Telix’s leading PSMA-PET imaging kit, Illucix, is used to perform gallium-68 PSMA-11 imaging exams in men with prostate cancer. The partnership covers North America and the European Union (excluding France and French speaking Belgium), the company said.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.